Seres Therapeutics

Yahoo Finance • 3 days ago

Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway

Following recent constructive FDA feedback, Seres anticipates finalizing SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant for the treatment of he... Full story

Yahoo Finance • 15 days ago

QuantumScape rallies as Seeking Alpha analyst pitches the upside

[Financial advisor interacts with a digital interface displaying machine learning data insights.] QuantumScape Corporation (NYSE:QS [https://seekingalpha.com/symbol/QS]) rallied in morning trading on Thursday as it took back ground lost o... Full story

Yahoo Finance • 16 days ago

Rapport Therapeutics prices $250M stock at $26 per share

* Rapport Therapeutics (NASDAQ:RAPP [https://seekingalpha.com/symbol/RAPP]) priced [https://seekingalpha.com/pr/20227241-rapport-announces-pricing-of-public-offering-of-common-stock] an underwritten public offering of 9.62M shares at a p... Full story

Yahoo Finance • 17 days ago

Biotech Stocks Surge After Hours: CAPR, TMDX Lead Gains Amid Trial Updates And Earnings Momentum

(RTTNews) - Several biotech and medical technology stocks posted notable gains in after-hours trading on Monday, with momentum driven by a mix of earnings optimism, clinical trial progress, and speculative positioning. While some names ral... Full story

Yahoo Finance • 17 days ago

Rapport launches proposed public offering of common stock

* Rapport Therapeutics (NASDAQ:RAPP [https://seekingalpha.com/symbol/RAPP]) has commenced an underwritten public offering of $250M of shares of its common stock. * RAPP -5.61% after hours to $29.76. * Source: Press Release [https://s... Full story

Yahoo Finance • 18 days ago

Top movers in Monday's pre-market session

Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. [premarket] TODAY'S PRE-MARKET GAINERS TICKER CHANGE COMMENT HOUR [https://www.ch... Full story

Yahoo Finance • 30 days ago

Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference

CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C. Wainwright Global Investment Conference in... Full story

Yahoo Finance • 2 months ago

Earnings call transcript: Seres Therapeutics reports larger-than-expected Q2 loss

Seres Therapeutics Inc. (MCRB) reported a larger-than-expected loss for Q2 2025, with earnings per share (EPS) at -$2.27, significantly below the forecast of -$0.09. The company’s stock experienced a minor dip, reflecting investor concerns... Full story

Yahoo Finance • 2 months ago

Seres Therapeutics Inc (NASDAQ:MCRB) Reports Q2 2025 Earnings: Narrower EPS Loss but Shares Dip in Pre-Market

Seres Therapeutics Inc (NASDAQ:MCRB [https://www.chartmill.com/stock/quote/MCRB]) reported its second-quarter 2025 financial results, posting revenue of $0.0 and an earnings per share (EPS) loss of $2.27. While revenue was in line with ana... Full story

Yahoo Finance • 2 months ago

Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

Seres Therapeutics, Inc. Following FDA input, Seres submitted Phase 2 study protocol to FDA for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to... Full story

Yahoo Finance • 2 months ago

Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025

CAMBRIDGE, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on August 6, 2025 at... Full story

Yahoo Finance • 4 months ago

Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting

CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading live biotherapeutics company, today announced the Company will be presenting new exploratory biomarker data from... Full story

Yahoo Finance • 6 months ago

Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Recent FDA feedback received on SER-155 allogeneic hematopoietic stem cell transplant (allo-HSCT) next study provides support for the proposed primary efficacy endpoint of reduction in bloodstream infections (BSIs) at day 30 post-HSCT; Com... Full story

Yahoo Finance • 2 years ago

11 Oversold NASDAQ Stocks To Buy Right Now

In this article, we will be taking a look at 11 oversold NASDAQ stocks to buy right now. To skip our detailed analysis of current stock market news, you can go directly to see the 5 Oversold NASDAQ Stocks To Buy Right Now. NASDAQ Leads Th... Full story

Yahoo Finance • 2 years ago

Seres Therapeutics, Inc. (NASDAQ:MCRB) is a favorite amongst institutional investors who own 62%

Key Insights Given the large stake in the stock by institutions, Seres Therapeutics' stock price might be vulnerable to their trading decisions The top 5 shareholders own 52% of the company Ownership research along with analyst forecasts... Full story

Yahoo Finance • 2 years ago

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Seres Therapeutics, Inc. (NASDAQ: MCRB) and Encourages Investors to Contact the Firm

PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Seres Therapeutics, Inc. (NASDAQ: MCRB) (“Seres”) on behalf of the company’s investors. Since June 2023, shares of Seres’ common stock ha... Full story

Yahoo Finance • 2 years ago

INVESTOR ALERT: Abbott Cooper PLLC Announces Investigation into Seres Therapeutics, Inc.; Urges Seres Stockholders to Contact Abbott Cooper Regarding Their Legal Rights

STAMFORD, Conn., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”) on behalf of the Company’s investors. The investigation seeks to determine whether... Full story

Yahoo Finance • 2 years ago

Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry

The company's MIMiC™ platform drives unprecedented insights into molecular interactions to design new biomolecules precisely tuned for therapeutic benefit With $50 million in committed capital from Flagship, Metaphore has built a first-in... Full story

Yahoo Finance • 3 years ago

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2022 Earnings Call Transcript

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2022 Earnings Call Transcript March 7, 2023 Operator: Thank you for holding, and welcome everyone, to the Seres Therapeutics Fourth Quarter 2022 Conference Call. . Thank you. I will now turn the c... Full story

Yahoo Finance • 3 years ago

Q4 2022 Seres Therapeutics Inc Earnings Call

Participants Carlo Tanzi; IR Officer; Seres Therapeutics, Inc. David A. Arkowitz; Executive VP, CFO & Head of Business Development; Seres Therapeutics, Inc. David S. Ege; Executive VP & CTO; Seres Therapeutics, Inc. Eric D. Shaff; Pres... Full story